BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 35147457)

  • 1. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
    Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
    J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK.
    Bielack S; Fox CP; Hoang-Xuan K; Giró-Perafita A; Rizzari C
    Health Sci Rep; 2024 Jan; 7(1):e1749. PubMed ID: 38186937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing and Managing Toxicities of High-Dose Methotrexate.
    Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
    Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance.
    Ramsey LB; Balis FM; O'Brien MM; Schmiegelow K; Pauley JL; Bleyer A; Widemann BC; Askenazi D; Bergeron S; Shirali A; Schwartz S; Vinks AA; Heldrup J
    Oncologist; 2018 Jan; 23(1):52-61. PubMed ID: 29079637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury.
    Heuschkel S; Kretschmann T; Teipel R; von Bonin S; Richter S; Quick S; Alakel N; Röllig C; Balaian E; Kroschinsky F; Knoth H; Bornhäuser M; von Bonin M
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):41-48. PubMed ID: 34669022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
    Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
    Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Survey of Methotrexate Prescription and Blood Concentration in Patients Treated with High-Dose Methotrexate].
    Kobayashi S; Yasu T; Momo K; Ohno N
    Gan To Kagaku Ryoho; 2020 Jul; 47(7):1063-1067. PubMed ID: 32668853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing.
    Ibarra M; Combs R; Taylor ZL; Ramsey LB; Mikkelsen T; Buddington RK; Heldrup J; Barreto JN; Guscott M; Lowe J; Hurmiz C; Marada S; Howard SC; Schaiquevich P
    Br J Clin Pharmacol; 2023 Feb; 89(2):660-671. PubMed ID: 35998099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
    Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
    Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucarpidase for the treatment of life-threatening methotrexate overdose.
    Tuffaha HW; Al Omar S
    Drugs Today (Barc); 2012 Nov; 48(11):705-11. PubMed ID: 23170306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
    Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
    Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
    Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity - a review of pharmacological and clinical data.
    Kielbowski K; Rosik J; Bakinowska E; Gromowska E; Ustianowski Ł; Szostak B; Pawlik A
    Expert Opin Drug Metab Toxicol; 2023; 19(11):741-750. PubMed ID: 37846862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Dose Methotrexate: Nursing Considerations for Administration and Supportive Care.
    Roche B; Clarke PA; Ford D; Collins Shaver S; Thompson J
    Clin J Oncol Nurs; 2023 Jan; 27(1):47-54. PubMed ID: 37677820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity.
    Widemann BC; Hetherington ML; Murphy RF; Balis FM; Adamson PC
    Cancer; 1995 Aug; 76(3):521-6. PubMed ID: 8625136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
    Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
    Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury.
    Sakran R; Milo G; Jabareen A; Artul T; Haim N; Litvak M; Ringelstein-Harlev S; Horowitz N; Efrati E; Assady S; Kurnik D
    J Oncol Pharm Pract; 2022 Mar; 28(2):508-515. PubMed ID: 34668443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
    Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
    Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia?
    Barakat S; Assem H; Salama M; Mikhael N; El Chazli Y
    J Egypt Natl Canc Inst; 2022 Apr; 34(1):17. PubMed ID: 35434757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.